Effects of H2 blockers and omeprazole on peptic secretion: a prospective, randomized study in duodenal ulcer subjects.
Aim of the present study has been to investigate the possible modifications of peptic secretion after a period with H2 blockers and omeprazole, evaluating in the same patient pepsinogen group A levels in gastric mucosa and pepsin in gastric juice. 54 active duodenal ulcer were studied: during an upper gastrointestinal endoscopy a sample of gastric juice and one fundus biopsy were taken before and after four weeks 300 mg/daily ranitidine (23 patients), 40 mg/daily famotidine (7 patients), 300 mg/daily nizatidine (12 patients) therapy and 40 mg/daily omeprazole (12 patients) therapy.


RESULTS
H2-blockers and omeprazole treatment determines a non statistically significant decrease of pepsin in gastric juice and in pepsinogen group A in gastric mucosa.
Di Mario
F
F
Istituto di medicina interna, Cattedra malattie apparato digerente, Università degli studi di Padova.
Dotto
P
P
Vianello
F
F
Germanà
B
B
Grassi
S A
SA
Del Favero
G
G
Faggian
D
D
Plebani
M
M
Naccarato
R
R
D000328:Adult; D000368:Aged; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D016567:Nizatidine / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use*; D010434:Pepsin A / Q000378:metabolism*; D010435:Pepsinogens / Q000378:metabolism; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use
D006635:Histamine H2 Antagonists; D010435:Pepsinogens; D015738:Famotidine; D011899:Ranitidine; D010434:Pepsin A; D009853:Omeprazole; D016567:Nizatidine